Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP Followed by Zevalin for Stages I and II CD20+ Diffuse Large Cell Lymphoma
NCT00088881Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2004
- Primary completion
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Primary endpoints: Complete Response + Complete Response/Uncertain and Functional Complete Response. Started Dec 2004; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00088881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088881.